Brain natriuretic peptide (BNP) gene expression is a well documented marker of hypertrophy in the cardiac myocyte. Triiodothyronine (T 3 ), the bioactive form of thyroid hormone, triggers a unique form of hypertrophy in cardiac myocytes that accompanies the selective activation or suppression of specific gene targets. In this study, we show that the BNP gene is a target of T 3 action. BNP secretion was increased 6-fold, BNP mRNA levels 3-fold, and BNP promoter activity 3-5-fold following T 3 treatment. This was accompanied by an increase in myocyte size, sarcomeric organization, and protein synthesis. Of note, several of the responses to T 3 synergized with those to the conventional hypertrophic agonist endothelin. The response to the liganded thyroid hormone receptor (TR) was mediated by an unusual thyroid hormone response element located between ؊1000 and ؊987 relative to the transcription start site. Both TR homodimers and TR⅐retinoid X receptor heterodimers associated with this element in an electrophoretic mobility shift assay. Protein fragments harboring the LXXLL motifs of the coactivators GRIP1 and SRC1 or TRAP220 interacted predominantly with the TR⅐retinoid X receptor heterodimeric pair in a liganddependent fashion. Both TR homodimers and heterodimers in the unliganded state selectively associated with glutathione S-transferase-nuclear receptor corepressor fragments harboring one of three receptor interaction domains containing the sequence (I/L)XX-(I/V)I. These interactions were dissociated following the addition of T 3 . Collectively, these findings identify the BNP gene as a potential model for the investigation of TR-dependent gene regulation in the heart.
The heart is highly sensitive to the effects of thyroid hormone. Triiodothyronine (T 3 ), 1 the most active form of thyroid hormone, increases heart rate, cardiac contractility (direct and indirect effects), and cardiac output. Pathological states associated with either hypo-or hyperthyroidism display abnormalities in cardiac function that frequently contribute to the morbidity and mortality associated with these disorders (1) . T 3 has also been shown to activate growth in cardiac myocytes in vitro (2, 3) and in vivo (4, 5) , through a combination of direct and indirect effects, leading to increased cell size, protein synthesis, and changes in gene expression. Thyroid hormone regulates a number of genes in the heart, including those encoding sarcoplasmic endoplasmic reticulum Ca 2ϩ -ATPase (SERCA) (6, 7) , atrial natriuretic peptide (8) , ␤ 1 -adrenergic receptors (9) , ␣-myosin heavy chain (␣-MHC) (2, 3, 10) , ␤-myosin heavy chain (␤-MHC) (2, 3, 10, 11) , Na ϩ /K ϩ -ATPase (12), voltage-gated K ϩ channels (13) , phospholamban (14) , type V and VI adenylyl cyclases (15) , Na ϩ -Ca 2ϩ exchanger (16, 17) , and the thyroid hormone receptor (TR) itself (3) . T 3 -dependent effects appear to be unique from those associated with so-called pathological hypertrophy (e.g. that due to hemodynamic overload in vivo) in that T 3 treatment of the pathologically hypertrophied myocardium produces a shift in the gene expression profile away from that which is typically identified with pathological hypertrophy alone (18) and toward a profile more closely resembling the physiological hypertrophy associated with exercise training (3) .
Brain natriuretic peptide (BNP) is a cardiac hormone that is linked closely with hypertrophy both in animal models (19) and humans (20, 21) . Thyroid hormone has been shown to stimulate secretion of BNP in vitro and in vivo (22) . However, there is no evidence to indicate that this is accompanied by changes in BNP gene expression in the cardiac myocyte, nor have these changes been linked to the hypertrophic phenotype.
Thyroid hormone exerts its effects in target cells through interaction with high affinity nuclear receptors present in chromatin (23) . These receptors associate with cognate DNA recognition elements, termed thyroid hormone response elements (TREs), as monomeric, homodimeric, or heterodimeric (typically partnered with the related retinoid X receptor (RXR)) complexes. These, in turn, interact with coregulatory nuclear proteins that promote enhanced (coactivators) or reduced (corepressors) transcriptional activity. The p160 family of coactivators (e.g. glucocorticoid receptor-interacting protein (GRIP1/TIF2/NCoA-2), the steroid receptor coactivator (SRC1/ NCoA-1), and the coactivator for the nuclear hormone receptor (ACTR/pCIP/Rac3/AIB1/TRAM-1)) associate with the liganded * This work was supported by National Institutes of Health Grant HL35753 and American Heart Association Grant 9950062N. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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TR and promote assembly with additional regulatory proteins (e.g. CBP (cAMP-responsive element-binding protein-binding protein and p300) harboring histone acetyltransferase activity that is capable of modifying chromatin structure in a manner that leads to increased gene transcription (24) . The TR has also been shown to interact with a second class of coactivators collectively termed the TRAP (TR-associated protein)-DRIP (vitamin D receptor-interacting protein) complex (25) . This complex is capable of promoting receptor-dependent transcription on naked DNA, presumably by fostering contacts with the core transcriptional apparatus (26, 27) . There are two corepressor molecules (i.e. nuclear receptor corepressor (NCoR) (28, 29) and SMRT (silencing mediator for retinoid and thyroid hormone receptors) (29, 30) ), each of which forms a suppressor complex with the unliganded TR, as well as other proteins possessing histone deacetylase activity, and represses transcription.
In this study, we have identified the BNP gene as a target of thyroid hormone action in the myocardial cell. Interaction of the liganded TR with the BNP gene promoter takes place largely through a single TRE located ϳ1 kb upstream from the start site of transcription. This interaction provides the substrate for assembly of various coactivator and corepressor complexes that control transcription of this gene.
EXPERIMENTAL PROCEDURES

Materials-[␣-
32 P]dCTP, [␥-32 P]ATP, and [ 3 H]leucine were purchased from PerkinElmer Life Sciences. Endothelin-1 and the BNP radioimmunoassay kit were obtained from Phoenix Pharmaceuticals, Inc. T 3 was obtained from Sigma. Anti-human (h) TR␤ and anti-hRXR␣ antibodies were purchased from Santa Cruz Biotechnology, Inc. The TNT T7 Quick-Coupled Transcription/Translation system was purchased from Promega. All oligonucleotides were synthesized by Invitrogen. Other reagents were obtained through standard commercial suppliers.
Cell Culture-Ventricular myocytes were prepared from 1-day-old neonatal rat hearts by alternate cycles of 0.05% trypsin digestion and mechanical disruption as described previously (31) . Cells were cultured in Dulbecco's modified Eagle's medium containing 10% enriched calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin for 24 h. Cells were changed to serum-free medium containing 2 mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin prior to initiation of each experiment.
BNP Radioimmunoassay-The culture medium of each well was collected after 24 h of treatment and centrifuged to remove cellular debris; the supernatant was taken for assay. Radioimmunoassay was performed according to the instructions provided by the manufacturer (Phoenix Pharmaceuticals) using rabbit antiserum specific for rat BNP- 45 and 125 I-labeled rat BNP-45. Protein Synthesis-Protein synthesis was assessed by measuring [ 3 H]leucine incorporation into cultured ventricular myocytes. Cells were cultured in 24-well plates for 24 h and then changed to serum-free medium and subjected to treatment for 48 h. Cells were pulsed with [ 3 H]leucine in leucine-free medium for the final 4 h of the treatment period, washed three times with phosphate-buffered saline (PBS), and extracted with 10% trichloroacetic acid at 4°C for 30 min. Cell residues were rinsed in 95% ethanol, solubilized in 0.25 N NaOH for 2 h, and neutralized with 2.5 mM HCl plus 1 mM Tris-HCl (pH 7.5). Radioactivity was measured in a liquid scintillation counter and normalized to cell number.
RNA Isolation and Northern Blot Analysis-Total RNA was isolated from cultured ventricular myocytes using RNAzol (LPS Industries Inc., Moonachie, NJ). Fifteen g of RNA was size-fractionated on a 1.2% agarose gel containing 2% formaldehyde, transferred to a nitrocellulose membrane, and hybridized simultaneously with 32 P-labeled 640-bp rat BNP cDNA and 32 P-labeled 1.3-kilobase pair glyceraldehyde-3-phosphate dehydrogenase cDNA. The membrane was washed and exposed to x-ray film. Autoradiographic signals were scanned and quantified by NIH Image. Normalized data are presented as the ratio of BNP to glyceraldehyde-3-phosphate dehydrogenase mRNA levels in individual samples.
Plasmid Construction and Site-directed Mutagenesis-The construction of Ϫ1595hBNP-luciferase has been described previously (32) . Expression vectors for human TR␣ (33), TR␤ (34), RXR␣ (35) , and GRIP1 (36) have also been described previously, as have expression vectors encoding the GST-NCoR-His fusion proteins of the three NCoR receptor interaction domains (RIDs) (37) . The latter included RID1 (NCoR residues 2231-2321), RID2 (residues 2034 -2114), and RID3 (residues 1888 -2031). GST-GRIP1 (amino acids 618 -770) was amplified by standard PCR methodology from pSG5-GRIP1 using synthetic primers incorporating EcoRI and SalI sites at the 5Ј and 3Ј termini of the coding sequence, respectively. Amplified DNA was restricted with EcoRI and SalI and cloned into the EcoRI and SalI sites of the bacterial expression vector pGEX-5X (Amersham Biosciences). The GST-mutant GRIP1 (mGRIP1) expression vector was constructed in a similar fashion, except that pSG5-mGRIP1 was used as a template. mGRIP1 contains double alanine substitutions of two leucines (LXXLL 3 LXXAA) in nuclear receptor boxes 2 (residues 685-701) and 3 (residues 740 -756) (36) . The latter are required for TR binding to GRIP1. GST-TRAP220 has been reported previously by Yuan et al. (38) . GST-SRC1 was constructed by linking residues 632-752 of SRC1 to six His residues at the carboxyl terminus of the fragment. An NdeI site was then added to the amino terminus and a SalI site to the carboxyl terminus of the chimeric fragment using conventional PCR methodology. The resultant fragment was cloned between the NdeI and SalI sites of pGEX-5X. Site-directed mutagenesis was carried out with the QuikChange kit (Stratagene, La Jolla, CA) using conditions recommended by the manufacturer. The sequence of the TRE mutagenic primer (sense strand) was as follows (mutagenized bases are identified by lowercase letters): 5Ј-CGATCTCCTtAtCaCGcGATCCGACCGCCTCG-3Ј.
Transfection and Luciferase Assay-Freshly prepared ventricular myocytes were transiently transfected with the indicated reporters (6 g/1.5 ϫ 10 7 cells) and expression vectors (see figure legends for DNA concentrations) by electroporation (Gene-Pulser, Bio-Rad) at 280 mV and 250 microfarads. DNA content in individual cultures was normalized with pUC18. Cells were plated (1.25 ϫ 10 6 /well) and cultured in Dulbecco's modified Eagle's medium/H-21 containing 10% enriched calf serum for 24 h. Cells were then changed to serum-free medium overnight prior to treatment. Cells were harvested and lysed in 200 l of cell culture lysis reagent (Promega). Cell lysates were processed for the luciferase assay as described (32) using a commercially available kit (Promega). Luciferase levels were normalized for concentrations of soluble protein in the extracts. To ensure reproducibility, experiments were repeated with three to five independent cell preparations.
Immunostaining-Ventricular myocytes were cultured in four-chamber slides for 24 h and then changed to serum-free medium and subjected to treatment for 48 h. Cells were washed with PBS and incubated with 3.7% paraformaldehyde at room temperature for 20 min, followed by PBS containing 0.2% Triton for 2 min. Cells were blocked with PBS containing 0.2% bovine serum albumin and 0.1 g/ml normal horse IgG and incubated with mouse anti-rat sarcomeric ␣-actinin antibody (EA-53, Sigma) at 4°C overnight. Cells were washed three times with PBS and incubated with Texas Red-conjugated horse anti-mouse secondary antibody (Vector Labs, Inc., Burlingame, CA) at room temperature for 30 min. After three consecutive washes, cells were mounted with Vectashield mounting medium and viewed by fluorescence microscopy. Linear dimensions and surface areas of individual cells were calculated using semiautomatic computer-assisted planimetry from two-dimensional images.
Expression and Purification of GST Fusion Proteins from Escherichia coli-GST fusion expression vectors were transformed into the BL21 strain of E. coli (Stratagene), expanded in suspension culture, and induced with 1 mM isopropyl-␤-D-thiogalactopyranoside. Cells were pelleted; sonicated in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% Tween 20; and centrifuged at 15,000 ϫ g. The supernatant was decanted, added to 300 l of glutathione-Sepharose beads, and rotated at 4°C for 1 h. The mixture was transferred to a 10-ml Poly-Prep chromatography column (Bio-Rad) and washed three times with PBS containing 0.1% Nonidet P-40. Elution buffer containing 50 mM TrisHCl (pH 8.0), 5 mM glutathione, and 1 mM dithiothreitol was added to the column, and the elute was collected in 200-l fractions. Protein concentration was measured using Coomassie reagent. The peak fractions were pooled and dialyzed against 50 mM Tris-HCl (pH 8.0) at 4°C overnight. GST fusion protein was aliquoted and stored at Ϫ80°C prior to use.
Electrophoretic Mobility Shift Assay (EMSA)-Oligonucleotides encoding wild-type and mutant TREs (both sense strand) were as follows (TRE-like sequence is underlined, and mutagenized bases are identified by lowercase letters): wild type, 5Ј-CGATCTCCTGACCTCGTGATCC-GACCGCCTCG-3Ј; and mutant, 5Ј-CGATCTCCTtAtCaCGcGATCCGA-CCGCCTCG-3Ј. Oligonucleotides used for scanning mutagenesis were as follows: wild type, 5Ј-CGATCTCCTTGACCTCGTGATCCGACCGC-CTCG-3Ј; M1, 5Ј-CGATCTCCTTaAaaTCGTGATCCGACCGCCTCG-3Ј; M2, 5Ј-CGATCTCCTTGACCTCGTaATaaGACCGCCTCG-3Ј; M3, 5Ј-CGATCTCCTTGACCTCGTGATCCataaGCCTCG-3Ј; M4, 5Ј-CGATCTCCTTGACCTCGTGATCCGACCaaaTCG-3Ј; and M5, 5Ј-CGATaTaaTTG-ACCTCGTGATCCGACCGCCTCG-3Ј. hTR␤ or hRXR␣ was synthesized in vitro using the TNT T7 Quick-Coupled Transcription/Translation system according to the manufacturer's instructions. Two l of each in vitro translated protein was incubated with purified 32 P-end-labeled, double-stranded oligonucleotide in binding reaction buffer containing 10 mM HEPES (pH 7.9), 50 mM KCl, 2 mM EDTA, 2.5 mM dithiothreitol, 10% glycerol, 0.05% Nonidet P-40, and 0.5 g of poly(dI-dC) at room temperature for 30 min. For competition experiments, a 10 -50-fold molar excess of unlabeled, double-stranded oligonucleotide was added to the binding reaction. For cofactor assembly experiments, varying amounts of GST-GRIP1, GST-SRC1, GST-TRAP220, or GST-NCoR RID1-3 fragments were added to the binding reaction in the absence or presence of 10 nM T 3 . For immunoperturbation experiments, 1 g of polyclonal antibody directed against TR␤ or RXR␣ was included in the reaction. All samples were resolved on 5% nondenaturing polyacrylamide gels. Gels were dried and exposed to x-ray film to generate autoradiographs.
Statistics-Data were analyzed using one-way analysis of variance and the Newman-Keuls test to assess significance.
RESULTS
We began by examining the ability of T 3 to increase expression of the BNP gene in neonatal rat ventricular myocytes. As shown in Fig. 1A , exposure to T 3 for 48 h resulted in a Ͼ6-fold increment in release of BNP immunoreactivity from cultured myocytes. This was accompanied by a 3-fold increase in steadystate BNP mRNA transcript levels (Fig. 1B ). For reference, endothelin (ET), a well documented activator of BNP gene expression (39, 40) and hypertrophy (41) in this in vitro model, effected an almost 8-fold increase in BNP mRNA levels; however, the combination of ET plus T 3 resulted in an increase in transcript levels (ϳ20-fold) that was clearly greater than additive, implying a synergistic interaction between these two agonists. T 3 effected a modest increase (2-3-fold in this experiment) in BNP promoter activity, whereas ET increased activity by ϳ10-fold (Fig. 1C) . Once again, ET plus T 3 synergistically increased promoter activity by Ͼ60-fold.
Given the known ability of both T 3 and ET to promote distinct forms of hypertrophy of myocardial cells in vitro (2, 41) and in vivo (4, 42) , we examined the effects of these agents on conventional markers of hypertrophy in the cultured myocyte model. As shown in Fig. 2A , T 3 and ET stimulated protein synthesis, assessed as [ 3 H]leucine incorporation, by ϳ2.5-and 4-fold, respectively. The combination of both agents was roughly additive, with a net induction of ϳ7-fold. Morphologically, both T 3 and ET increased cell size and sarcomeric organization in these cultured myocytes (Fig. 2B) . The effect was somewhat more pronounced with ET versus T 3 . Calculation of linear dimensions of cells cultured under each of these conditions showed that ET increased both the length and width of the individual myocytes, whereas T 3 preferentially affected the length (Fig. 2C) . Myocyte surface area was increased by both agents. In each instance, the combination of both agents led to an increase in cell dimensions and enhanced sarcomeric definition to a level that surpassed that with either agent alone, supporting the protein synthesis data described above.
T 3 effected a dose-dependent increment in BNP promoter activity that peaked at 10 Ϫ8 M, with a maximal induction of FIG. 1. Effect of T 3 and ET, alone or in combination, on immunoreactive BNP secretion, BNP mRNA levels, and BNP promoter activity in neonatal rat ventricular myocytes. After 24 h of culture, cells were changed to serum-free medium and treated with 10 nM T 3 , 100 nM ET, or both in combination for 48 h. A, the medium was collected and subjected to radioimmunoassay. B, 15 g of total RNA was subjected to blot hybridization analysis. Blots were hybridized simultaneously with radiolabeled BNP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes. Autoradiographs were quantified by NIH Image and normalized for glyceraldehyde-3-phosphate dehydro- 5-6-fold (Fig. 3A) . Amplification of the response was seen following cotransfection with either hTR␣ or hTR␤ (Fig. 3B) . Both TR␣ and TR␤ are known to be expressed endogenously in neonatal rat cardiac myocytes (3) . Maximal induction with TR␤ was ϳ7.5-fold in this series of studies, whereas that with TR␣ was in the range of 4-fold.
As noted above, the liganded TR is thought to exert most of its transcriptional effects through association with its cognate TRE. This leads to subsequent association with one of several coactivators that, in turn, promote downstream events (histone acetylation, complex assembly on the promoter, etc.), resulting in increased transcriptional activity. As shown in Fig. 4 , the addition of T 3 to the cultures resulted in a 3-fold increment in BNP-luciferase activity, which was increased to 5-fold following cotransfection with the hTR␤ expression vector and to 9-fold following cotransfection with both hTR␤ and the heterodimeric partner RXR. Little or no suppression of basal activity by unliganded TRs was observed, suggesting that the majority of the T 3 effect that was observed corresponded to positive enhancement of promoter activity rather than relief of basal repression. Of note, cotransfection of the coactivator molecule GRIP1 together with TR␤ and RXR resulted in a significant increase in basal promoter activity (this was dependent on the concentration of GRIP1 expression vector added to the cells), which increased even further following the addition of T 3 . The relative induction (i.e. -fold induction) seen following GRIP1 cotransfection was lower than that seen in cells transfected with TR␤ alone or TR␤⅐RXR, reflecting the elevation in basal promoter activity; however, the absolute magnitude of the inductions was clearly greater in those cultures cotransfected with GRIP1. The elevation in basal promoter activity likely reflects the ability of the p160 coactivators to amplify the activity of other non-ligand-dependent transcription factors (43) that may control the activity of this promoter.
Next, we attempted to identify the location of the TRE responsible for trafficking the liganded TR signal on the BNP gene promoter. Careful scrutiny of the known sequence for candidate sites revealed a potential TRE at Ϫ1000 that showed a high degree of homology to the consensus TRE (Fig. 5A) (44) . Our initial impression was that the TRE was arrayed as two direct repeats in reverse orientation. The 5Ј-repeat is a complete match to the consensus half-site (TGACCT; AGGTCA on the lower strand). There were possible matches to a 3Ј-repeat (four of six positions) in both direct repeat (DR) 2 (TGATCC; GGATCA on the lower strand) and DR7 (CGACCG; CGGTCG on the lower strand) configurations. Introduction of several nucleotide changes across this element (see Fig. 5A for description of mutations) resulted in virtually complete abrogation of the T 3 -dependent induction of the BNP gene promoter (Fig. 5B) while exerting no significant effect on basal promoter activity. Note that the bulk of the nucleotide changes were introduced in the upstream consensus half-site. Interestingly, this same mutation resulted in a partial reduction (ϳ40 -45%) in ET-dependent activation of the BNP promoter (Fig. 5C) , suggesting a potential explanation for the synergistic interaction between ET and T 3 noted above.
Using an EMSA, we explored the ability of the TR and RXR stained with monoclonal antibody directed against sarcomeric ␣-actinin, and processed for fluorescence microscopy. All images were taken at the same magnification (ϫ400). C, myocyte length, width (each at maximal dimension), and surface area were measured using semiautomatic computer-assisted planimetry as described under "Experimental Procedures." Twenty cells from each group were randomly selected for measurement of surface area in each experiment. Pooled data from three independent experiments are presented as means Ϯ S.D. *, p Ͻ 0.01 versus control; **, p Ͻ 0.01 versus ET. to associate with this TRE in vitro. As shown in Fig. 6A , TR homodimers associated with a labeled 32-bp oligonucleotide encoding the TRE from the BNP promoter. This association was completely inhibited by wild-type sequence (i.e. unlabeled, but otherwise identical double-stranded nucleotide), but not by a mutant sequence identical to that produced for the functional studies carried out for Fig. 5 . The RXR did not bind appreciably to the TRE, but the TR⅐RXR heterodimer bound well and migrated in a position that was readily separated from the homodimer. Once again, unlabeled wild-type sequence (even when reduced to 10-fold excess), but not mutant sequence, proved capable of disrupting this interaction. Of note, when mutations were introduced into the candidate half-sites of the DR2 element alluded to above (Fig. 6B) , only those in the consensus half-site (M1) significantly impaired binding of the heterodimer to DNA (Fig. 6C) . Mutations in the putative nonconsensus DR2 half-site (M2), as well as two additional downstream sites in or near the putative DR7 half-site (M3 and M4) and one upstream site (M5), had no effect on heterodimer binding to the TRE. When the analysis was repeated for TR homodimer binding, M1 again proved most critical for the DNA-protein interaction. M2, M4, and M5 had no effect, whereas M3 (in sequences within the possible DR7 half-site) also showed a significant reduction in homodimer binding (Fig. 6C) .
Because the BNP TRE did not adhere to the exact DR4 consensus, we further examined the properties of the BNP TRE-bound TR homodimeric and heterodimeric complexes in EMSAs. The TRE-bound TR⅐RXR heterodimers also proved capable of interacting with members of the p160 class of coactivator proteins in this EMSA. As shown in Fig. 7A , the heterodimer, as well as the TR homodimer, associated with the TRE in the absence of ligand. The addition of T 3 effected a modest alteration in the binding intensity and migration pattern (slightly faster migration pattern) of the heterodimeric complex. The addition of a GST-linked GRIP1 fragment (amino acids 618 -770), which contains the LXXLL motif required for association with the TR (36), led to the appearance of a slower mobility band on the gel. The addition of ligand enhanced this band considerably and resulted in a reduction in the intensity of the signal identified with the isolated heterodimeric complex. The mutant GRIP1 construct mGRIP1, with a mutation in the LXXLL motif (36), was, as expected, unable to interact with the heterodimeric complex in the presence or absence of ligand. A receptor-binding fragment of SRC1 (amino acids 632-752), another member of the p160 coactivator family, also showed evidence of modest interaction with the heterodimeric complex in the absence of ligand; and again, the addition of T 3 resulted in amplification of the putative receptor⅐coactivator complex. Finally, the heterodimer also appeared to be capable of associating with a GST-linked fragment of TRAP220 (amino acids 622-701), a subunit of the TRAP complex that has previously been shown to interact with the TR⅐RXR heterodimer (38) , putatively providing a molecular link to the core transcriptional machinery. As shown in Fig. 7A, TRAP220 , like the p160 coactivators, associated with the heterodimer to a modest degree in the absence of ligand; and again, this association increased dramatically following the addition of T 3 . The addi- tion of T 3 effected a significant reduction in TR homodimer association with the BNP TRE (Fig. 7B) ; however, as with the heterodimer described above, there was evidence of a slight interaction of the unliganded homodimer with the GST-GRIP1, GST-SRC1, and GST-TRAP220 fragments, and this interaction increased modestly, albeit not to the levels seen with the heterodimer, following the addition of T 3 .
To provide assurance that the coactivator-shifted complexes did, in fact, contain the TR⅐RXR heterodimer, we perturbed the shifted complexes with antibodies directed against hTR␤ and hRXR␣. As shown in Fig. 8 , anti-TR␤ antibody successfully supershifted the TR⅐RXR complex as well as the GST-GRIP1-and GST-SRC1-shifted complexes. Antibody directed against the RXR was similarly effective in supershifting these same three complexes, implying that both the TR and RXR are present in the p160-dependent complexes that assemble in the presence of ligand.
Next, we investigated whether binding of GRIP1 and TRAP220 is mutually exclusive in the context of TR⅐RXR bound to DNA. Previous studies have suggested that the p160 coactivators and TRAP220 bind in a competitive fashion to receptor in solution (45) . As shown in Fig. 9 , the addition of increasing amounts of GRIP1 protein reduced TRAP220 binding to the DNA-bound heterodimer and vice versa. This suggests that these two coactivators, although structurally unrelated and possessed of independent regulatory activity, operate through association with the same or a similar interface on the receptor. Of incidental note, in addition to promoting assembly of the heterodimer into a slower migrating complex, TRAP220 also increased the levels of TR monomer bound to DNA, implying that this interaction promotes a fundamental alteration in receptor conformation.
Finally, it is known that the unliganded TR displays a propensity for association with the transcription-suppressing corepressors NCoR (27, 28) and SMRT (29, 30) . In the case of NCoR, this is thought to occur through association of the receptor(s) with one or more RID boxes present in the corepressor protein (37, 46 -48) . Recent studies indicate that the TR employs three RID boxes in the NCoR molecule to promote this association, whereas the unliganded estrogen receptor and RXR␣ largely employ RID1 and RID3 to effect stable interaction with NCoR (37) . As shown in Fig. 10 , the TR homodimer proved capable of interacting strongly with each of the three RID box-containing fragments (definition of the exact sequence incorporated in these individual constructs is presented under "Experimental Procedures"). In each case, the addition of T 3 predictably resulted in abrogation of the TR-NCoR interaction as well as dissociation of the TR homodimer from the BNP TRE. Interestingly, the unliganded TR⅐RXR heterodimer also proved capable of associating with the individual NCoR fragments.
FIG. 7.
Nuclear receptor coactivators preferentially assemble with the DNA-bound TR⅐RXR heterodimer in a T 3 -dependent fashion. A, 2 g of GST-GRIP1, GST-mGRIP1, GST-SRC1, or GST-TRAP220 was incubated with 32 Plabeled BNP TRE and 2 l each of hTR␤ and hRXR␣ in the absence or presence of 10 nM T 3 prior to running the EMSA. B, 2 l of hTR␤ was incubated with 32 P-labeled BNP TRE and 2 g of GST-GRIP1, GST-SRC1, or GST-TRAP220 in the absence or presence of 10 nM T 3 .
There was preferential association of the heterodimer with RID2 and, to a lesser extent, RID3, with little or no interaction with RID1. This suggests that the TR has the capacity to preferentially interact with selected domains in the NCoR molecule depending on whether it engages the TRE as a homodimeric or heterodimeric complex.
DISCUSSION
Several key findings emerge from this study. First, it provides the first identification of the BNP gene promoter as a target of thyroid hormone action in the heart. Second, it demonstrates that the effects of T 3 and ET, a more conventional hypertrophic agonist in this in vitro model (41) , interact functionally in promoting both the morphological changes associated with hypertrophy and activation of the BNP gene promoter. Third, it identifies the TRE in the BNP gene that provides the substrate for assembly of coregulatory complexes on this promoter. Finally, it identifies several features of complex assembly that appear to be unique to the DNA-associated TR.
The BNP response was temporally linked to the development of the hypertrophic phenotype, supporting the hypothesis that activation of BNP gene transcription serves as a marker of hypertrophy in this model (19) . The function of BNP in the in vivo setting of thyroid hormone excess is unknown. BNP could optimize cardiac performance through reduction in filling pressures and afterload (49) . Alternatively, it could act to control the progression and magnitude of the hypertrophic response through a local negative feedback loop (50, 51) , thereby limiting cardiac fibrosis, chamber remodeling, and progression to cardiomyopathy. The cardiac hypertrophy associated with thyroid hormone excess is notably deficient in accompanying fibrosis (52) .
The gene expression profile in pathological hypertrophy (i.e. that associated with hemodynamic overload in vivo or G protein-coupled receptor activation in vitro) closely resembles that associated with hypothyroidism in the cardiac myocyte, whereas physiological hypertrophy has been linked to changes in gene expression that more closely resemble those associated with thyroid hormone administration (3, 53) . This dichotomy has led some investigators to suggest that pathological hypertrophy may represent a state of functional hypothyroidism within the cardiac myocyte. In fact, Kinugawa et al. pathological hypertrophy generated by constriction of the rat ascending aorta in vivo. In a separate study, Kinugawa et al. (54) demonstrated a reduction in TR␣1 levels in failing human ventricular tissue with a coincident increase in the levels of TR␣2, a TR isoform that does not bind ligand, yet is capable of functioning in a dominant-negative mode to inhibit TR action. TR␤1 levels were unchanged relative to age-matched controls. These data remain controversial in that others have published conflicting findings (55-57), but they raise the intriguing possibility that relative TR deficiency may account for the functional hypothyroid picture that dominates the gene expression profile in pathological hypertrophy. Of note, Chang et al. (18) showed that thyroid hormone (in this case, thyroxine) administration to rats with left ventricular hypertrophy post-aortic banding normalized myocardial function with improved contractility, faster relaxation, and increased concentrations of ␣-MHC and SERCA proteins relative to those without thyroxine treatment. These data support the model discussed above and suggest that exogenous thyroid hormone can suppress at least some of the phenotypic features associated with pathological hypertrophy.
Although both ET and T 3 appear to stimulate activation of hypertrophic markers in these neonatal myocytes, the phenotype of myocytes treated with these agents is unique; and by inference, the qualitative features of the hypertrophy are distinct. T 3 promoted elongation of the myocytes with only a marginal increase in the overall surface area. On the other hand, ET appeared to increase both the length and width of the individual myocytes. The combination of both agents promoted an increase in total cell dimension and a dramatic increase in sarcomeric organization relative to either treatment alone. It is conceivable that these differences are related to the distinct phenotypic changes that accompany T 3 -induced versus pathological (e.g. overload-induced) hypertrophy in vivo.
Similar to the findings reported here, Kinugawa et al. (3) demonstrated an additive effect of T 3 and the hypertrophic agonist phenylephrine in increasing protein synthesis in cardiac myocyte cultures. However, unlike our results, they found that T 3 and phenylephrine acted in opposing fashion in regulating thyroid hormone-responsive genes in these cells. T 3 increased ␣-MHC and SERCA levels and suppressed ␤-MHC, whereas phenylephrine increased ␤-MHC and reduced ␣-MHC and SERCA. The combination of both T 3 and phenylephrine led to an intermediate response. A similar dichotomy was noted upon comparison of exercise (physiological)-induced versus aortic constriction (pathological)-induced hypertrophy in vivo, with the gene expression profile in the former more closely resembling that of T 3 treatment in vitro. In this study, ET and T 3 operated in synergistic fashion to drive expression of the BNP gene and activation of the hBNP promoter, implying that thyroid hormone and G protein-coupled receptors can operate in parallel rather than opposing fashion in governing gene expression. The mechanism underlying the synergy between ET and T 3 remains unclear. At least a portion of the ET prohypertrophic activity resides outside the TRE because deletions down to within 198 bp of the transcription start site, which effectively eliminate the TRE from the promoter, retain the ability to respond to ET (data not shown). On the other hand, the data presented in Fig. 5C indicate that the TRE mutant displays a subnormal response to ET (ϳ50% of the control response), implying that ET may indirectly influence signaling through the TR⅐TRE complex. The mechanism underlying this effect is unknown, but could involve alterations in TR binding to DNA, recruitment of coregulators to the TR⅐TRE complex, or assembly of the complex with the core transcriptional apparatus. Kinugawa et al. (3) also demonstrated TR isoform-specific effects on individual promoters in their study, with ␤-MHC, SERCA, and TR␤1 responding primarily to TR␤1 and ␣-MHC, as well as overall myocyte size, falling under the control of TR␣1. Based on the findings presented in Fig. 3B , the BNP gene appears to fall in the former category, primarily under the control of TR␤1; however, this finding is difficult to substantiate without concomitant measurement of exogenous (transfectant-expressed) TR levels, and additional studies using isoform-specific agonists will be required to provide definitive support for this conclusion.
The TR typically associates with direct repeats of the sequence AGGTCA in a DR4 configuration (33) , although numerous exceptions have been described in the literature (58) . The TRE that we have identified in the BNP gene promoter does not conform readily to this typical TR-binding configuration. The upstream consensus half-site (TGACCT; AGGTCA on the lower strand) appears to be absolutely required for both TR DNA binding and functional activity. Sequence requirements for monomer binding to the second "half-site" are either very liberal or nonexistent for heterodimer binding because mutations upstream and downstream from the consensus half-site had no effect on binding to DNA. Heterodimer-binding functional TREs consisting solely of half-sites have been described in other systems (55) (56) (57) , where it is assumed that relatively nonspecific contacts between contiguous DNA and one of the partners are sufficient to stabilize the complex. Sequence requirements for homodimer binding to the BNP TRE may be slightly more stringent because downstream mutations in the M3 region led to a significant reduction in TR-binding activity (Fig. 6, B and C) . One candidate half-site (CGACCG; CGGTCG on the lower strand) that is affected by this mutation is arrayed as a direct repeat with the consensus half-site with a 7-nucleotide spacer. The rather limited restrictions on TR binding to this site raise the possibility that other nuclear receptors may employ this same regulatory element to activate or suppress BNP gene transcription. In fact, our preliminary studies suggest that peroxisome proliferator-activated receptor-␣ (but not vitamin D receptor) also associates with this element (data not shown); however, mutation of this site does not interfere with peroxisome proliferator-activated receptor-␣-dependent regulation of the BNP promoter (data not shown), suggesting that the signal transduction system underlying the latter is not as straightforward as that for the TR. Moreover, the unusual nature of the BNP TRE may suggest why unliganded TRs failed to suppress basal BNP promoter activity; the extent of suppression of basal promoter activity varies according to the exact topology of the TR DNA-binding site (58) .
Despite its unusual configuration, both homodimeric (TR⅐TR) and heterodimeric (TR⅐RXR) complexes bound avidly to the TRE in the unliganded state. Moreover, the addition of ligand preferentially dissociates the homodimer (but not the heterodimer) from DNA, as reported previously for other TREs (59) . Both the BNP TRE-bound homodimer and heterodimer associated with the p160 coactivator (GRIP1 and SRC1) and TRAP220 binding motifs; and in all instances, this association was stimulated by the addition of ligand. However, the interaction was considerably stronger (both in the presence and absence of the ligand) with the heterodimer. Of note, the presence of the TRAP220 binding motif appeared to promote the binding of the TR monomer to DNA in either the presence or absence of ligand, a property not shared by the p160 coactivators, suggesting that TRAP220 promotes a fundamental and unique alteration in receptor conformation. Despite this and the apparent assembly of a TR⅐TRAP220 complex in the presence of ligand, the affinity of the isolated homodimer for DNA was reduced significantly in the presence of ligand.
It has been shown that the p160 coactivators and TRAP220 bind sequentially to the liganded TR complex to trigger increased transcriptional activity (25, 26, 60, 61) . Binding of the liganded DNA-bound heterodimer to GRIP1 versus TRAP220 is competitive in nature, implying that the LXXLL motifs in both fragments associate with a common receptor interface, a finding that supports those of Treuter et al. (45) , who found a similar competitive interaction between TRAP220 and TIF2 (transcriptional intermediary factor-2), the human homolog of GRIP1. Based on the studies presented in Fig. 9 , it appears that the affinity of the heterodimer for these two coactivators fragments is similar. If differential affinities of these coactivators for the TR⅐RXR complex do, in fact, exist in the intact cell, our findings may reflect a requirement for additional regulatory factors, not present in these assays, that might serve to amplify or reduce the affinity of the individual coactivators for the TR. Alternatively, the affinity of these fragments for the TR may not mirror that of their respective holoproteins.
The BNP TRE-bound homodimeric and heterodimeric complexes also interacted with corepressors. The ability of each of three RID boxes to associate with the unliganded but DNAassociated homodimeric TR was approximately equivalent, supporting the previous studies carried out using radiolabeled TR and GST-RID in solution (37) . This stands in contrast to the results obtained for hRXR␣ (with helix 12 deleted), which bound RID1 well and showed very little binding to RID3 and almost no binding to RID2, and for human estrogen receptor-␣ (with helix 12 deleted), which showed binding to RID1 and RID3, but not to RID2 (37) . Binding to the unliganded DNAbound TR⅐RXR heterodimer was distinct from each of the patterns in that RID2 established the strongest contact with the receptors, whereas RID3 displayed a lower level of binding, and RID1 showed effectively no binding at all. There was also an apparent reduction in the level of RID binding to the TR heterodimeric versus homodimeric complex, although this may reflect, in part, a reduced level of heterodimer versus homodimer association with the TRE itself. Collectively, these data suggest that association of unliganded receptors (estrogen receptor versus RXR versus homodimeric TR versus heterodimeric TR) with the transcriptional corepressors leads them to adopt conformations that permit formation of unique receptor-corepressor contacts. Similar heterogeneity in receptor-corepressor binding has been noted by Cohen et al. (47) , who found that the retinoic acid receptor binds preferentially to SMRT, whereas the TR prefers NCoR (47) . They attributed these selected interactions to sequence differences in the region in and around RID2 (termed N2 in their study) versus the equivalent region (S2) in SMRT as well as the presence of a TR-specific binding domain termed N3 (RID3 in this study) in NCoR that is absent in SMRT (48). Zamir et al. (62) have shown that the orphan nuclear receptor RevErb associates with NCoR (but not SMRT), also presumably based on differential binding affinities for the available binding motifs in these two corepressor proteins. Collectively, these studies support the notion that different affinities for individual receptor-RID interactions may dictate the selectivity of receptor-corepressor assembly on the promoters of target genes and the subsequent regulation of transcriptional activity. As a corollary of this, heterogeneity in RID box binding raises the possibility that peptidomimetic agents could be developed that selectively target specific receptor-corepressor interactions.
In summary, the BNP gene has been identified as a transcriptional target for the liganded TR in the cardiac myocyte. The TRE responsible for this activity in the BNP promoter is positioned approximately 1 kb upstream from the transcription start site and displays the capacity to interact with the TR and to assemble both coactivator and corepressor complexes in vitro. This system may prove to be an excellent model for investigation of thyroid hormone-sensitive gene expression in the heart.
